U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT06981325) titled 'Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients' on March 06.
Brief Summary: The study is an open-label, singel arm, prospective, multicenter phase II trial evaluating the efficacy and safety of Cemiplimab when applied as first-line therapy in patients with locally advanced basal cell carcinoma (BCC), which were not pretreated with hedgehog inhibitors (HHI).
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Basal Cell Carcinoma (BCC)
First Line Treatment
Intervention:
DRUG: Cemiplimab
Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle...